Clinical trial · no report yet · Phase 2
MASTER-2
Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
- NCT05231629 ↗
- Active, not recruiting
- University of Alabama at Birmingham
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 34 | |
| YouTube | 7 | |
| Podcasts | 5 |
The trial
ClinicalTrials.gov- Official title
- MRD-Guided Sequential Therapy For Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Dara-VRd intensification, Dara-R maintenance; AHCT intensification, Dara-R maintenance; AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance; AHCT intensification, Dara-R consolidation, Dara-R maintenance; Dara-VRd induction
- Arms
- Arm A · Experimental
- Arm B · Active comparator
- Arm C · Experimental
- Arm D · Active comparator
- Arm M · Other
- Enrollment
- 300 (estimated)
- Primary outcomes
- Depth of response obtained with 6 cycles of Dara-VRd
- Sustained MRD negativity
- Sponsor
- University of Alabama at Birmingham with Janssen Scientific Affairs, LLC, Sarah Cannon, coMMit, Myeloma Trials, Innovated
- Start
- Dec 13, 2023
- Primary completion
- Sep 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05231629 · updated Sep 22, 2026